Trials / Completed
CompletedNCT02726022
A Quality of Life Study of Peginterferon-Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C and Persistently Normal Alanine Transaminase (ALT) Levels
A Quality of Life Study of PEGASYS® (Peginterferon-Alfa2a) in Combination With COPEGUS® (Ribavirin) in Patients With Chronic Hepatitis C and Persistently Normal ALT Levels
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 114 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Participants with Chronic Hepatitis C (CHC) and normal ALT, who have been under treatment with peginterferon alfa-2a and ribavirin for at least 4 weeks, will be enrolled into this non-interventional, open-label study. The primary aim is to evaluate quality of life according to the 36-Item Short-Form Health Survey (SF-36) questionnaire, modified for the Greek population.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Peginterferon alfa-2a | As per treating physician discretion and according to summary of product characteristics. |
| DRUG | Ribavirin | As per treating physician discretion and according to summary of product characteristics. |
Timeline
- Start date
- 2007-02-01
- Primary completion
- 2011-07-01
- Completion
- 2011-07-01
- First posted
- 2016-04-01
- Last updated
- 2016-08-15
- Results posted
- 2016-08-15
Locations
10 sites across 1 country: Greece
Source: ClinicalTrials.gov record NCT02726022. Inclusion in this directory is not an endorsement.